Physician profile
Salman A Haq
NPI 1679524268
$79,374.80
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $12K · 2021: $9,904 · 2022: $2,500.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $55,108.54 | 2019-2022 | |
| Medtronic Vascular, INC. | $9,074.78 | 2019-2020 | |
| Medtronic, INC. | $3,765.13 | 2021 | |
| Abiomed | $2,395.47 | 2019 | |
| Amgen INC. | $2,028.14 | 2019-2022 | |
| Abbott Laboratories | $1,497.34 | 2019-2021 | |
| Bardy Diagnostics, INC. | $877.71 | 2020-2021 | |
| Medical Device Business Services, INC. | $832.85 | 2019 | |
| Cvrx, INC. | $626.66 | 2021 | |
| Janssen Pharmaceuticals, INC | $604.52 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $352.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $347.72 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $292.38 | 2019-2022 | |
| Preventice Services, LLC | $266.86 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $232.87 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $209.98 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $148.84 | 2019-2022 | |
| Biotronik INC. | $106.97 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $78.80 | 2019-2020 | |
| Amarin Pharma, INC. | $57.39 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $45.45 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.66 | 2020-2021 | |
| Pfizer INC. | $20.93 | 2021 | |
| Ekos Corporation | $14.24 | 2019 | |
| W. L. Gore & Associates, INC. | $13.91 | 2019 |
Research and ownership
$600.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.